178 related articles for article (PubMed ID: 25076326)
1. KRAS in pancreatic cancer.
Agarwal A; Saif MW
JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
[TBL] [Abstract][Full Text] [Related]
2. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
[TBL] [Abstract][Full Text] [Related]
3. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
5. Biological identification of ampullary adenocarcinomas.
Relias V; Saif MW
JOP; 2014 Jul; 15(4):306-7. PubMed ID: 25076327
[TBL] [Abstract][Full Text] [Related]
6. [Kras oncogene and pancreatic cancer: thirty years after].
Bournet B; Dufresne M; Selves J; Torrisani J; Cordelier P; Buscail L
Med Sci (Paris); 2013 Nov; 29(11):991-7. PubMed ID: 24280502
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
Krasinskas AM; Chiosea SI; Pal T; Dacic S
Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
[TBL] [Abstract][Full Text] [Related]
10. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
11. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
12. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
13. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.
Mohelnikova-Duchonova B; Brynychova V; Hlavac V; Kocik M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Melichar B; Soucek P
Cancer Chemother Pharmacol; 2013 Sep; 72(3):669-82. PubMed ID: 23934321
[TBL] [Abstract][Full Text] [Related]
14. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
15. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
[TBL] [Abstract][Full Text] [Related]
17. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
Maluf-Filho F; Kumar A; Gerhardt R; Kubrusly M; Sakai P; Hondo F; Matuguma SE; Artifon E; Monteiro da Cunha JE; César Machado MC; Ishioka S; Forero E
J Clin Gastroenterol; 2007; 41(10):906-10. PubMed ID: 18090159
[TBL] [Abstract][Full Text] [Related]
18. Survival in ampullary cancer: potential role of different KRAS mutations.
Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
[TBL] [Abstract][Full Text] [Related]
19. Roles for KRAS in pancreatic tumor development and progression.
di Magliano MP; Logsdon CD
Gastroenterology; 2013 Jun; 144(6):1220-9. PubMed ID: 23622131
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]